樂觀
$193.53
情境價格
$191.750
-1.994 (-1.04%)收盤時
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences.
Becton Dickinson (BDX) is a good buy right now due to its current price of $191.75, which is below the average analyst price target of $200, suggesting potential upside. The stock has a strong gross margin of 46.76% and a forward P/E ratio of 13.72, indicating solid profitability and reasonable valuation. However, the main risk is the recent dip in net income, with a reported loss of $31 million in Q2 2026, which could impact future performance.
Barclays
$165
2026-10-07
Barclays
2026-10-07
目標價
$165
BofA
$200
2026-08-31
BofA
2026-08-31
目標價
$200
RBC Capital
$190
2026-08-13
RBC Capital
2026-08-13
目標價
$190
Citi
$208
2026-08-13
Citi
2026-08-13
目標價
$208
RBC Capital
$180
2026-08-07
RBC Capital
2026-08-07
目標價
$180
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Global Health Experts Urge Improved Maternal and Infant Monitoring Technologies

BD Celebrates 65 Years of Manufacturing in Connecticut

BD Celebrates 65 Years of Manufacturing in Connecticut

BD Appoints Ferass Abuzaina as Worldwide President of Surgery Business Unit

BD Partners with U.S. Government to Boost Domestic Manufacturing
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Becton Dickinson (BDX) is a good buy right now due to its current price of $191.75, which is below the average analyst price target of $200, suggesting potential upside. The stock has a strong gross margin of 46.76% and a forward P/E ratio of 13.72, indicating solid profitability and reasonable valuation. However, the main risk is the recent dip in net income, with a reported loss of $31 million in Q2 2026, which could impact future performance.
15 analysts cover BDX: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 192.64.

Beldex @BeldexCoin recently published two research pieces, and I think they are interesting to look at together. One is about age verification: you only need to prove you are over 18, without handing over your birthday, identity, and nationality all at once. At the same time, it checks that the credential signature is real, that the age is actually derived from that birthday, that the same number is locked in the commitment, and that this number is not below 18. In the end, the other party only gets one result: you meet the age requirement. This is still research for now. Beldex Research Labs is next trying Bulletproof to make the proof smaller and push verification cost down further. It has not yet become a ready feature in BChat or the wallet. The other is VRF consensus. Beldex's current PoS already has a layer of random validator selection. What VRF aims to add is verifiable randomness: everyone can later verify whether the result of who got selected followed the rules, while before the draw it is harder to predict in advance who the next batch will be. The team currently places the VRF-based PoS hardfork in Q1 2027. This is also a later upgrade, not something already fully switched over on mainnet now. One is dealing with how much identity information should be exposed, and the other is dealing with how randomness in consensus should be proven. These two research lines at Beldex are actually quite consistent in direction: provide enough information, and avoid exposing extra information as much as possible.
展開本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。